Dundas Partners LLP Boosts ResMed Inc. Stake by 15%

Institutional investor now owns over 175,000 shares of medical equipment provider

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Dundas Partners LLP, an institutional investor, increased its holdings in shares of ResMed Inc. (NYSE:RMD) by 15.1% during the third quarter, according to a recent SEC filing. The firm now owns 175,117 shares of the medical equipment provider's stock, making it the 12th largest holding in its portfolio.

Why it matters

ResMed is a leading global provider of medical devices and cloud-connected solutions for sleep apnea and other respiratory conditions. The increase in Dundas Partners' stake suggests the firm sees continued growth potential in ResMed's business, which could signal broader investor confidence in the company's outlook.

The details

Dundas Partners purchased an additional 22,933 shares of ResMed during the third quarter, bringing its total position to 175,117 shares worth approximately $47.9 million. This represents about 0.12% of ResMed's outstanding shares. The firm cited ResMed's strong market position and innovative product pipeline as reasons for the increased investment.

  • Dundas Partners LLP increased its ResMed holdings during the third quarter of 2026.

The players

Dundas Partners LLP

An institutional investment firm that has increased its stake in medical equipment provider ResMed Inc.

ResMed Inc.

A global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions.

Got photos? Submit your photos here. ›

The takeaway

Dundas Partners' increased investment in ResMed suggests continued confidence in the company's growth prospects within the sleep apnea and respiratory device market. As a leading player in this space, ResMed's performance is closely watched by investors seeking exposure to the expanding medical technology sector.